Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease
about
Prevalence of antiplatelet therapy in patients with diabetes.Aspirin resistanceUse of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control studyMy health: whose responsibility? Low-dose aspirin and older peopleArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabPeripheral arterial disease.Preoperative aspirin use and acute kidney injury after cardiac surgery: A propensity-score matched observational study.A randomised controlled trial comparing a dietary antiplatelet, the water-soluble tomato extract Fruitflow, with 75 mg aspirin in healthy subjectsEffects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort studyGender dependence for a subset of the low-abundance signaling proteome in human platelets.Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.Dual antiplatelet therapy in secondary prevention of ischemic stroke: a ghost from the past or a new frontier?Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.Fruitflow®: the first European Food Safety Authority-approved natural cardio-protective functional ingredient.Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding.Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in ratsInvestigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug UsersManagement of transient ischemic attack: 2005.Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patientsSnapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines.A cross sectional survey of secondary prevention measures in patients with peripheral arterial disease in primary careLong term medical treatment of stable coronary disease.Targeting platelets for prevention and treatment of cardiovascular disease.Point-of-care platelet function testing.Oral anticoagulants and non-cardioembolic stroke prevention.Management of atherothrombotic risk factors in high-risk Canadian outpatients.Evaluation of the potentials of autologous blood injection for healing in diabetic foot ulcers.Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.Platelet function and inhibition in ischemic heart disease.Medicinal Plants with Antiplatelet Activity.Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study.The influence of clopidogrel on ischemia diagnosed by myocardial perfusion stress testing.Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaids-associated ulcers complication.Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?Atherothrombosis and the role of antiplatelet therapyANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
P2860
Q24813940-961CB7ED-2E89-4E75-93BE-C137CB67EE66Q28187611-FD9EFC37-6919-4113-8661-0B0665FC479AQ28200506-BEE48EBC-91DA-48E0-9DA9-5306187F0260Q28201631-CF51F378-18E5-49AB-86DD-099557D4220EQ28219257-A04C091E-043C-4A89-AD12-088C8CDAC016Q30863696-C6364B0B-7BCC-4BE5-99AB-4EA3A8C74586Q33638287-377B6430-F69C-4EA1-82A6-23062CA44A87Q33795282-BA231384-494B-4981-A4F9-E6F65619662EQ34154557-56F8FD7D-787A-4C33-BD50-51275FABE770Q34219541-C2B5A58F-2240-4DF1-8B16-D5BB61C3DDB2Q34449178-883F38A4-C8CD-4106-B517-B9CC9A9C4365Q34479105-232D4DB5-EE15-4438-AAA3-21D1D1103167Q34487244-F43FB9AC-85BF-4235-9F14-D361A8227781Q34533314-C670EABD-2E4E-4341-9268-FEE8E51F3096Q35147463-1582F03C-F536-4100-84C0-6FB696A6C76EQ35398540-B8021639-D31B-448A-9C4E-EEA8409D472BQ35857875-AA4F50C4-31A9-4FBC-8D78-0FEE9AA2A99FQ36216801-85124175-1BF9-45C8-B725-4AE95FE1102EQ36881941-FC06EE4A-5A93-4B14-BE2F-5C90092E1DF0Q36924615-83A524BF-FFA7-4996-B5C8-C6AFC3ACADCBQ36933036-80C75221-D9DE-4959-9570-DBA70498600CQ36969811-345BD204-D337-49D4-8141-8F433D662CDAQ37004721-53647853-3BE4-485C-BCA4-ED931EAD712DQ37083098-E28F02F0-58A0-49CB-8A40-EDB2241DE823Q37121384-85F1F7FB-FCF8-44DD-9779-315E30EEF9AEQ37293740-8601FB5F-FA7C-4D28-BE54-C404BB91D145Q37578003-66E9B5BE-FE35-468E-B6E0-3C55226025FBQ37943829-C2652013-BA29-446F-9AC9-086B257AF3D6Q38007894-85B0397F-1347-416F-9006-B6853C8D5E60Q38803630-C6908BB6-E43D-47FC-9A50-466DB3B18173Q39862966-D4C1D7F7-CC58-4390-9C37-86DC442BC0F3Q40575675-0D635059-E3F3-4ECE-85D2-E1D28D879A2CQ44485195-1A3A12BA-0867-4992-B0B9-332371BDD8FDQ46427553-99241229-B24B-4CDC-B0A8-876FC5881F18Q57243374-6FB5DCE3-0F25-4CEA-9F7C-3EE4CC705E0AQ57764209-3FCA024D-AE2F-497E-B784-58EC479B8155
P2860
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@ast
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@en
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@nl
type
label
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@ast
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@en
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@nl
prefLabel
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@ast
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@en
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@nl
P3181
P356
P1476
Oral antiplatelet therapy in c ...... nd peripheral arterial disease
@en
P2093
Huyen Tran
Sonia S Anand
P304
P3181
P356
10.1001/JAMA.292.15.1867
P407
P577
2004-10-20T00:00:00Z